{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:09:35Z","timestamp":1790258975057,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Skin fibrosis is increasingly recognized as an important component of chronic inflammatory skin diseases, contributing to dermal thickening, tissue stiffness, and persistent functional impairment. Although transforming growth factor-\u03b2 (TGF-\u03b2) has long been considered the central mediator of fibrosis, accumulating evidence indicates that interleukin-13 (IL-13), a key cytokine of type 2 immunity, plays a pivotal role in linking chronic inflammation to fibrotic remodeling. Unlike classical scar formation, IL-13-associated fibrosis is characterized by sustained immune activation, continuous extracellular matrix remodeling, and residual tissue plasticity, suggesting that it represents a dynamic and potentially reversible process. In this review, we summarize the current understanding of the mechanisms by which IL-13 promotes skin fibrosis. We discuss direct activation of fibroblasts through the IL-13R\u03b11\/STAT6 pathway, dysregulation of extracellular matrix synthesis and degradation, neuroimmune interactions involving chronic itch and mechanotransduction, macrophage\u2013fibroblast crosstalk, and emerging evidence for fibroblast memory mediated by epigenetic remodeling. Furthermore, we compare the pathological features of IL-13-associated fibrosis across representative skin diseases, including atopic dermatitis, prurigo nodularis, systemic sclerosis, and keloids. This conceptual framework provides a unified perspective on the diverse roles of IL-13 in cutaneous fibrosis and highlights the importance of integrating immunological, mechanical, and stromal mechanisms.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1974049","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:55:26Z","timestamp":1790258126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-13 and skin fibrosis in inflammatory skin diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Noriko","family":"Ikegawa","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health","place":["Kitakyushu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan Manh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health","place":["Kitakyushu, Japan"]},{"name":"Department of Dermatology, Hanoi Medical University","place":["Hanoi, Vietnam"]},{"name":"Department of Dermatology, National Hospital of Dermatology and Venereology","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Saito-Sasaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health","place":["Kitakyushu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Occupational and Environmental Health","place":["Kitakyushu, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100422","article-title":"Nanostring transcriptomic analysis highlights IL-6 family and TGF-\u03b2 pathways in the pathogenesis of prurigo nodularis","volume":"6","author":"Akiska","year":"2026","journal-title":"JID Innov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40257-026-01007-4","article-title":"Radiotherapy-induced skin fibrosis: pathophysiology, emerging therapeutics, and the role of dermatology","volume":"27","author":"Burke","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1834346","article-title":"Epithelial-mesenchymal transition in cutaneous fibrosis disease: from mechanisms to therapy","volume":"17","author":"Yuan","year":"2026","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn7871","article-title":"Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.12.002","article-title":"Skin fibroblasts in health and disease: from extracellular matrix remodeling to immune regulation","volume":"146","author":"Marella","year":"2026","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s1462399403005817","article-title":"Skin repair and scar formation: the central role of TGF-beta","volume":"5","author":"Beanes","year":"2003","journal-title":"Expert Rev Mol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01551-9","article-title":"Immunology of human fibrosis","volume":"24","author":"Bhattacharya","year":"2023","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100504","article-title":"IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin","volume":"186","author":"Oh","year":"2011","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.06.003","article-title":"Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin","volume":"26","author":"Allen","year":"2014","journal-title":"Semin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"25066","DOI":"10.1038\/srep25066","article-title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics","volume":"6","author":"O'Reilly","year":"2016","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.005","article-title":"Interleukin-4 receptor \u03b1 signaling in myeloid cells controls collagen fibril assembly in skin repair","volume":"43","author":"Knipper","year":"2015","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee","year":"2001","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.jaci.2020.02.026","article-title":"ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation","volume":"145","author":"Leyva-Castillo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-007-0051-x","article-title":"IL-13 receptor isoforms: breaking through the complexity","volume":"7","author":"Tabata","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1084\/jem.20020903","article-title":"Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response","volume":"197","author":"Chiaramonte","year":"2003","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41598-024-84151-3","article-title":"Regulation of fibronectin and collagens type I, III and VI by TNF-\u03b1, TGF-\u03b2, IL-13, and tofacitinib","volume":"15","author":"Gillesberg","year":"2025","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","article-title":"Basic mechanisms of itch","volume":"152","author":"Misery","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.03.009","article-title":"Periostin, an emerging player in itch sensation","volume":"141","author":"Hashimoto","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179935","article-title":"Critical players and therapeutic targets in chronic itch","volume":"23","author":"Yang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1272230","article-title":"Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch","volume":"16","author":"Mahmoud","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"19589","DOI":"10.1038\/s41598-023-46237-2","article-title":"IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages","volume":"13","author":"Scott","year":"2023","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110203","article-title":"Cellular crosstalk in fibrosis: insights into macrophage and fibroblast dynamics","volume":"301","author":"Froom","year":"2025","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1972","article-title":"Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis","volume":"6","author":"Habermann","year":"2020","journal-title":"Sci Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112131","article-title":"Platelet-instructed SPP1(+) macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner","volume":"42","author":"Hoeft","year":"2023","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112840","article-title":"Fibroblast memory in development, homeostasis and disease","volume":"10","author":"Kirk","year":"2021","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.07.005","article-title":"Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab","volume":"153","author":"Ma","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00149-x","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18225","article-title":"Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options","volume":"36","author":"Bieber","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/jci200421060c","article-title":"New insights into atopic dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1165098","article-title":"The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.295","article-title":"Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling","volume":"129","author":"Zheng","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40257-024-00913-9","article-title":"Biomarkers in atopic dermatitis: a review of the role of IL-13 and the impact of tralokinumab treatment","volume":"26","author":"Gorelick","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2025.03.010","article-title":"The big four in the pathogenesis and pathophysiology of prurigo nodularis: interplay among type 2 inflammation, epidermal hyperplasia, dermal fibrosis, and itch from neuroimmune dysregulation","volume":"43","author":"Hashimoto","year":"2025","journal-title":"Clin Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","article-title":"Chronic prurigo including prurigo nodularis: new insights and treatments","volume":"25","author":"M\u00fcller","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.04.019","article-title":"Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis","volume":"152","author":"Alkon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1092685","article-title":"Dupilumab for the treatment of prurigo nodularis: a systematic review","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2026.2654771","article-title":"The patient journey in prurigo nodularis: what lies ahead","volume":"26","author":"Scala","year":"2026","journal-title":"Expert Opin Biol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1383\/medc.30.10.36.28247","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1016\/j.jbspin.2019.11.008","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.18502\/ijaai.v23i2.15325","article-title":"Interferon-\u03b3 induces interleukin-6 production and alpha-smooth muscle actin expression in systemic sclerosis fibroblasts","volume":"23","author":"Rokni","year":"2024","journal-title":"Iranian J Allergy Asthma Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70063","article-title":"Salirasib inhibits the expression of genes involved in fibrosis in fibroblasts of systemic sclerosis patients","volume":"12","author":"Sadeghi Shaker","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","article-title":"The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications","volume":"24","author":"Rokni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.imlet.2017.10.002","article-title":"Current perspectives on the role of CD8+ T cells in systemic sclerosis","volume":"195","author":"Fuschiotti","year":"2018","journal-title":"Immunol Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154799","article-title":"Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis","volume":"125","author":"Gasparini","year":"2020","journal-title":"Cytokine"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8222-1","article-title":"Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-beta signaling and the fibrotic response","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12131","article-title":"CCN2 expression by fibroblasts is not required for cutaneous tissue repair","volume":"22","author":"Liu","year":"2014","journal-title":"Wound Repair Regener"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am J Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","article-title":"Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin","volume":"12","author":"Tabib","year":"2021","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117630","article-title":"An updated review of the immunological mechanisms of keloid scars","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030711","article-title":"Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030606","article-title":"Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis","volume":"18","author":"Ogawa","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(24)35380-7","article-title":"Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts","volume":"292","author":"Oriente","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157091","article-title":"IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK\/STAT6 activation","volume":"8","author":"Chao","year":"2023","journal-title":"JCI Insight"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207109","article-title":"Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis","volume":"75","author":"Huang","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molmed.2019.02.001","article-title":"The role of epigenetic modifications in systemic sclerosis: a druggable target","volume":"25","author":"Henderson","year":"2019","journal-title":"Trends Mol Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"J Scleroderma Related Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1974049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:55:27Z","timestamp":1790258127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1974049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2026.1974049"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1974049","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1974049"}}